课题基金 / 基金详情

EFFECT OF LIPID MODIFICATION ON PERIPHERAL ARTERIAL DISEASE AFTER ENDOVASCULA

EFFECT OF LIPID MODIFICATION ON PERIPHERAL ARTERIAL DISEASE AFTER ENDOVASCULA
脂质修饰对血管内术后周围动脉疾病的影响
批准号:
7375042
负责人:
ALAN LUMSDEN
金额:
$2.36万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2005
资助国家:
美国
项目状态:
已结题
起止时间:
2005-12-01 至 2006-11-30

项目摘要

项目成果

ALAN LUMSDEN的其他基金

相似基金

相关文献

中文摘要
翻译
本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者(PI)可能已经从另一个NIH来源获得了主要资金,因此可以在其他CRISP条目中表示。列出的机构是中心的,不一定是研究者的机构。据估计,外周动脉疾病(PAD),一种系统性动脉粥样硬化的表现,发生在大约12%的成年人中,在美国影响了大约800万到1000万人。轻至中度PAD最常见的症状表现是间歇性跛行,65岁以上人群的年发病率为2%。与同龄的健康对照组相比,这些患者的死亡风险明显更高。然而,尽管PAD患病率高,且与心血管疾病发病率和死亡率有很强的相关性,但人们对该疾病的关注相对较少,与冠状动脉疾病患者相比,PAD患者因其动脉粥样硬化危险因素而接受适当治疗的可能性较小。冠状动脉和PAD最常见的心血管危险因素包括吸烟、糖尿病、高血压、血脂异常和同型半胱氨酸代谢异常。几个大型临床试验已经确定降低冠状动脉疾病患者胆固醇浓度的益处。在PAD患者中,他汀类药物治疗不仅可以降低血清胆固醇浓度,还可以改善内皮功能,以及其他动脉粥样硬化风险指标,如血清p -选择素浓度。治疗可改善外周动脉疾病患者的心血管预后。PAD不仅会增加心血管疾病的发病率和死亡率,而且间歇性跛行患者的功能状态也会严重受损。跛行患者的峰值运动表现约为同龄对照组的50%,按照纽约心脏协会的标准,这相当于中度至重度心力衰竭。行走能力有限导致残疾,尤其不利于生活质量,因为休闲和工作活动往往受到严重限制。这种残疾会极大地限制正常活动,由于在没有干预的情况下改善是罕见的,因此缓解间歇性跛行的治疗是必不可少的。目前存在几种治疗下肢PAD的技术。外科血运重建术是一种可行的选择,因为即使在早期阶段,围手术期死亡率和发病率的相关风险也很低。此外,PTA(经皮血管成形术)手术有良好的并发症和长期通畅率,随着血管内支架的出现而改善。踝肱血压指数(ABI)降低反映出PAD的诊断与心脑血管事件的风险高度相关。这一认识导致了这样的建议,即诊断应导致风险增加。虽然踝关节肱指数降低是心血管疾病发病率的标志,但关于跛行患者的数据较少,对跛行患者进行干预,下肢动脉粥样硬化的进展可能是通畅和症状缓解的最终决定因素。本研究将通过评估强化联合脂质修饰治疗与标准脂质修饰治疗在预防血管内干预后动脉粥样硬化和再狭窄进展中的新方法的效果,来检查有症状的PAD患者危险因素修饰的结果。
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. It is estimated that peripheral arterial disease (PAD), a manifestation of systemic atherosclerosis, occurs in approximately 12% of the adult population and affects about 8 million to 10 million people in the United States. The most common symptomatic manifestation of mild to moderate PAD is intermittent claudication occurring at an annual incidence of 2% in people over 65 years of age. These patients are at a significantly higher risk of death compared with healthy controls of a similar age. However, despite the high prevalence of PAD and its strong association with cardiovascular morbidity and mortality, the disease receives relatively little attention, and PAD patients are less likely to receive appropriate treatment for their atherosclerotic risk factors than those with coronary artery disease. The most common cardiovascular risk factors for coronary artery and PAD include smoking, diabetes, hypertension, dyslipidemia, and abnormalities of homocysteine metabolism. Several large clinical trials have determined the benefits of lowering cholesterol concentrations in patients with coronary artery disease. In PAD, treatment therapy with a statin not only lowers serum cholesterol concentrations, but also improves endothelial function, as well as other markers of atherosclerotic risk, such as serum P-selectin concentrations. Treatment may improve cardiovascular outcomes in persons with peripheral arterial disease. Not only are cardiovascular morbidity and mortality increased with PAD, but functional status is often severely impaired in patients with intermittent claudication. Peak exercise performance in the claudicating patient is about 50% that of age-matched controls, which is equivalent to moderate to severe heart failure using New York Heart Association criteria. The limited ability to ambulate leads to a disability that is particularly detrimental to quality of life because both leisure and work activities are often severely curtailed. This disability can limit normal activities substantially and because improvement in the absence of an intervention is rare, therapy to relieve intermittent claudication is essential. Several therapeutic techniques currently exist for the treatment of PAD in the lower extremities. Surgical revascularization is a viable alternative because the associated risks of periprocedural mortality and morbidity are low, even at an early stage. In addition, PTA (percutaneous angioplasty) procedures have favorable complication and long-term patency rates which have improved with the advent of endovascular stents. The diagnosis of PAD which is reflected in a lowered ankle-brachial blood pressure index (ABI), is highly correlated with the risk of cardiac and cerebrovascular events. This recognition has led to the recommendation that the diagnosis should lead to increased risk modification. Although lowered ankle brachial index is well documented as a marker for cardiovascular morbidity in general, there is less data on the patient who presents with claudication, where intervention is performed for claudication and in whom the lower extremity progression of atherosclerosis is likely to be the ultimate determinant of patency and relief of symptoms. This study will examine the outcomes of risk factor modification in symptomatic PAD patients by evaluating the effects of administering an intensive combination lipid modifying therapy versus a standard lipid modifying therapy in a novel approach to preventing progression of atherosclerosis and restenosis following an endovascular intervention.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
EFFECT OF LIPID MODIFICATION ON PERIPHERAL ARTERIAL DISEASE AFTER ENDOVASCULA
  • 批准号:
    7605937
  • 项目类别:
  • 资助金额:
    $2.78万
  • 财政年份:
    2007
  • 负责人:
    ALAN LUMSDEN
  • 依托单位:
THROMBIN MECHANISMS OF VASCULAR GRAFT FAILURE
  • 批准号:
    6239073
  • 项目类别:
  • 资助金额:
    $4.21万
  • 财政年份:
    1997
  • 负责人:
    ALAN LUMSDEN
  • 依托单位:
THROMBIN MECHANISMS OF VASCULAR GRAFT FAILURE
  • 批准号:
    5210755
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    --
  • 负责人:
    ALAN LUMSDEN
  • 依托单位:
    --
国内基金
海外基金
新肿瘤靶标 DHCR24/Lipid-Rafts 轴在急性髓系白血病中的作用和分子机制研究
  • 批准号:
    LQ22H080007
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2021
  • 负责人:
    吴照星
  • 依托单位:
4-胺基阿拉伯糖基修饰的活性寡糖分子lipid A及衍生物的合成研究
  • 批准号:
    22007080
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    24.0万元
  • 批准年份:
    2020
  • 负责人:
    朱玉根
  • 依托单位:
CRISPR/Cas9基因编辑 PLGA/Lipid纳米可视递送系统靶向治疗骨关节炎的作用机制研究
  • 批准号:
    2020A151501615
  • 项目类别:
    省市级项目
  • 资助金额:
    10.0万元
  • 批准年份:
    2020
  • 负责人:
    于博
  • 依托单位:
CRISPR/Cas9基因编辑PLGA/Lipid纳米可视递送系统靶向治疗骨关节炎的作用机制研究
  • 批准号:
    81974323
  • 项目类别:
    面上项目
  • 资助金额:
    55.0万元
  • 批准年份:
    2019
  • 负责人:
    于博
  • 依托单位: